Principal Financial Group Inc. Sells 6,274 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Principal Financial Group Inc. decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 45.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,497 shares of the company’s stock after selling 6,274 shares during the quarter. Principal Financial Group Inc.’s holdings in Dyne Therapeutics were worth $269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Sei Investments Co. bought a new position in shares of Dyne Therapeutics in the 1st quarter valued at about $693,000. Seven Eight Capital LP raised its position in Dyne Therapeutics by 195.7% during the second quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock valued at $1,896,000 after purchasing an additional 35,568 shares during the period. Mutual of America Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $1,724,000. Vanguard Group Inc. boosted its holdings in shares of Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of Dyne Therapeutics in the 2nd quarter worth approximately $676,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on DYN. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Stifel Nicolaus raised their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at approximately $3,405,524.40. This represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the transaction, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,257 shares of company stock valued at $6,193,718. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Stock Down 0.8 %

DYN opened at $29.45 on Tuesday. The stock’s fifty day moving average is $32.06 and its two-hundred day moving average is $35.40. The company has a market capitalization of $3.00 billion, a P/E ratio of -8.27 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52 week low of $10.12 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.